The Medtronic study demonstrated the PulseSelect PFA system’s effectiveness in creating lesions during Afib treatment. Credit: JHVEPhoto / Shutterstock.

Medtronic has announced new clinical study results showcasing a high durable lesion formation rate for the PulseSelect pulsed field ablation (PFA) system in atrial fibrillation (Afib) treatment.

The study, presented at the Asia Pacific Heart Rhythm Society meeting, indicated that 98% of pulmonary veins remained isolated approximately two months post-ablation.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study involved 25 patients with persistent or paroxysmal Afib, demonstrating a 98% durability rate in pulmonary vein isolation (PVI) using the PulseSelect PFA system.

Invasive remapping conducted on average 57 days post-ablation showed that 96% of patients had all veins isolated.

All index ablation procedures were performed using intracardiac echocardiography and electroanatomical mapping, avoiding fluoroscopy.

The majority of patients were under general anaesthesia, and the average skin-to-skin procedure time was recorded at 36 minutes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With acute PV isolation achieved in 100% of patients and no complications reported during an average follow-up of 74 days, the data underscores the system’s safety and effectiveness.

Medtronic cardiovascular portfolio’s cardiac ablations solutions business president Rebecca Seidel said: “These important results clearly address the durability question and add to the real-world evidence for PulseSelect.

“With an expansion in new markets across the Asia Pacific region, physicians around the world are experiencing the benefits of PulseSelect, including proven safety, efficacy, efficiency and now durability as well. We are thrilled to provide this important tool to physicians for the treatment of patients with Afib.”

The PulseSelect PFA system has seen broad adoption, with more than 10,000 cases performed globally, including regulatory approvals and launches in the Asia Pacific region.

Afib affects over 60 million individuals worldwide and remains one of the most common yet undertreated heart rhythm disorders.

Before this development, Medtronic announced a partnership with Siemens Healthineers to expand access to advanced imaging technologies within the field of spine care.